SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN CRYPTO is actively trending, fueled by its strong, culture-first community on Solana, which champions a long-term "Bongterm" vision. The token is celebrated as the digital representation of global cannabis culture, with ongoing discussions emphasizing its positive community energy and potential for future growth. Enthusiasts are rallying around the mantra "Like Bitcoin But Way Higher," highlighting shared belief and patience.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending as news circulates about its acquisition of VLX-1005 and advancements for its lead candidate, tecarfarin, including manufacturing progress and a pivotal Phase 3 trial collaboration with Abbott. The investment community is actively discussing tecarfarin's potential as a next-generation anticoagulant with Fast Track designation for a significant market, yet considerable skepticism persists regarding the company's financial strategy and alleged bot-driven social media activity.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending following news of a multi-billion dollar government investment aimed at securing domestic critical mineral supply chains. This substantial funding, structured as an equity stake and additional financing, has sparked significant community excitement, with many anticipating a considerable increase in valuation and discussing the potential for a short squeeze. The development reinforces broader efforts to establish an integrated mine-to-magnet supply chain and reduce reliance on foreign sources for essential materials.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending amidst widespread controversy following a recent incident involving federal agents and an American citizen in Minneapolis, igniting fierce debate within the community regarding civil liberties and law enforcement tactics. Many are condemning the event as an unjustified killing, while others defend the actions of federal agents against alleged interference, amplifying the polarized political discussion surrounding the company. This comes as broader market anxieties, including potential government shutdown threats and international trade tensions, contribute to heightened investor attention.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. ($BNAI) is experiencing intense trending activity driven by a significant short squeeze, with community chatter focusing on a low share float and high borrow rates creating immense pressure on short positions. Discussion among traders centers on the stock's potential for extended gains as short sellers face considerable challenges, drawing comparisons to other historical squeeze events.

Zoracles

Zora Crypto is currently trending as the community anticipates a significant market reversal and a potential altcoin season, fueled by upcoming legislative developments like the Clarity Act and shifts in monetary policy. Investors are actively accumulating tokens, expressing both excitement for its long-term potential and patience through recent volatility, highlighting its role in the creator economy on Coinbase's Base ecosystem and its positioning in real-world asset tokenization.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is a top trending stock as the community eagerly awaits the release of critical 3-year durability data for its Duchenne gene therapy, Elevidys. Discussions are highly polarized, with many anticipating robust results to ignite a substantial short squeeze and confirm the company's long-term value, while others remain wary of past market reactions and ongoing regulatory scrutiny. This highly anticipated data is widely considered a pivotal moment, shaping expectations for future market performance and potential strategic interest.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as its US subsidiary submitted a consolidated deep-seabed mining application to NOAA, a critical step enabled by updated regulations that expand its potential recovery area. The community is highly bullish, driven by the perceived national security imperative to secure essential critical minerals and reduce foreign supply chain dependence. Investors are actively discussing the anticipation of rapid permit approval, strong government backing, and the potential for a significant short squeeze.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is trending as its ongoing transformation gains momentum, driven by proactive cost-cutting measures and CEO-led reorganization efforts that leverage AI for efficiency. This strategic overhaul, coupled with recent analyst upgrades and progress in resolving regulatory oversight, is bolstering investor confidence in the bank's long-term profitability. While discussions include potential impacts from proposed credit card rate caps, the community is actively debating Citi's potential for sustained growth and its ventures into digital assets.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively discussed following compelling Phase 1 data for its oral ITK inhibitor, soquelitinib, in atopic dermatitis, which some believe positions it favorably against existing treatments due to its efficacy and safety profile. This has fueled a divided community, with many anticipating substantial future appreciation and potential partnerships, while others remain cautious, citing the company's early clinical stage and recent capital raise as reasons for skepticism regarding its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat reports...

Q4 EPS Estimates for TG Therapeutics Raised by HC Wainwright

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at HC Wainwright raised their Q4 2025 earnings per share estimates for TG Therapeutics in a research report issued to clients and...

TG Therapeutics (NASDAQ:TGTX) Trading 7.5% Higher - Here's Why

TG Therapeutics (NASDAQ:TGTX) Stock Price Up 7.5% - Here's What Happened...

HC Wainwright Forecasts TG Therapeutics FY2025 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at HC Wainwright raised their FY2025 EPS estimates for TG Therapeutics in a research report issued to clients and investors on...

Currency and Exchange Stock Chart for Finance and Economy Display. (Image Courtesy: Getty Images)

TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally

Strong 2026 guidance and accelerating uptake of its MS drug send TGTX to its best session in months, with Wall Street and retail piling in.

Equity

TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) saw some unusual options trading on Wednesday. Investors purchased 7,870 call options on the company. This is an increase of 119% compared to the...

TG Therapeutics (NASDAQ:TGTX) Shares Gap Up - Time to Buy?

TG Therapeutics (NASDAQ:TGTX) Shares Gap Up - What's Next...

TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results

TGTX jumps after preliminary 2025 sales beat guidance. Its bullish 2026 revenue target and multiple Briumvi pipeline milestones also draw attention.

<ul class="summary-bullets"><li>The company sees 2025 revenue of $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.</li><li>BRIUMVI’s U.S. net product revenue expected to reach around $182 million in Q4 and $594 million in 2025.&nbsp;</li><li>TG Therapeutics stock rallies 9% higher in Wednesday’s premarket.&nbsp;</li></ul>TG Therapeutics, Inc. (TGTX) drew increased attention on Wednesday, with the stock seeing a 195% increase in retail chatter on Stocktwits over the last 24 hours following the company’s ambitious revenue outlook.&nbsp;On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.<h2 class="st-heading-2">What Did Stocktwits Users Say?&nbsp;</h2><a href="https://stocktwits.com/symbol/TGTX">TG Therapeutics stock</a> traded over 9% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_14_083034_png_390ef2e760.webp" alt="TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits" width="933" height="108"><figcaption>TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded optimistic about BRIUMVI achieving blockbuster status.<stembedurl>https://stocktwits.com/knowthyself/message/641747123</stembedurl>Another bullish user said the company’s ramp-up from Q3 to Q4 was impressive.&nbsp;<stembedurl>https://stocktwits.com/Uncle_Baby_Billy/message/641752748</stembedurl><h2 class="st-heading-2">Outlook Highlights&nbsp;</h2>TG Therapeutics expects BRIUMVI’s U.S. net product revenue to reach around $182 million in Q4 and $594 million for the full year of 2025. Global revenue for the year is estimated at $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.&nbsp;Looking ahead, the company anticipates total global revenue between $875 million and $900 million for 2026, with U.S. BRIUMVI sales projected at $825 million to $850 million.BRIUMVI is a glycoengineered monoclonal antibody that targets CD20-expressing B-cells, a proven approach for treating autoimmune diseases like relapsing multiple sclerosis (RMS). By removing specific sugar molecules, BRIUMVI enhances B-cell depletion at lower doses.<h2 class="st-heading-2">Upcoming Clinical Milestones</h2>The company also teased three major milestones for 2026.&nbsp;TG Therapeutics plans to release pivotal topline data for the ENHANCE trial, which evaluates Day 1 and Day 15 intravenous doses of BRIUMVI, by mid-2026. Preliminary Phase 1 data for azer-cel in Progressive multiple sclerosis (MS) will be shared in the latter half of the year.&nbsp;Pivotal topline results for subcutaneous BRIUMVI are expected by year-end 2026 or early 2027.&nbsp;TGTX stock has declined by over 6% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Biology lab technician removes a freeze-dried sample from a container in a laboratory.

Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.

<ul class="summary-bullets"><li>TG Therapeutics CEO Michael S. Weiss said on Tuesday that the company continues to believe Briumvi has a “multi-billion dollar opportunity.” &nbsp;</li><li>In FY26, the company expects Briumvi’s U.S. revenue to come in between &nbsp;$825 million and $850 million, accounting for a major chunk of the company’s overall revenue. &nbsp;</li><li>Briumvi is a prescription medication used to treat adults with relapsing forms of multiple sclerosis (MS).</li></ul>Shares of TG Therapeutics Inc (TGTX) rallied 7% after hours on Tuesday after the company said that it now expects full year 2026 total global revenue of $875 million to $900 million, highlighting significant growth expectations for its blockbuster drug Briumvi.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-provides-preliminary-fourth-quarter-and-full-1">expects</a> total revenue for full year 2025 to be about $616 million, including $594 million from sales of its Briumvi in the U.S. This exceeds a Wall Street estimate of $606.03 million, according to data from Fiscal AI.<h2 class="st-heading-2">Briumvi Demand</h2>TG Therapeutics Michael S. Weiss said on Tuesday that the company continues to believe Briumvi has a “multi-billion dollar opportunity.” &nbsp;Briumvi is a prescription medication used to treat adults with relapsing forms of multiple sclerosis (MS). Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the myelin sheath, the protective covering of nerve cells in the brain and spinal cord. This damage disrupts nerve signals, leading to a wide range of neurological symptoms, including numbness, vision problems, and difficulties with balance, coordination, and walking.The company is now also looking to develop and seek approval for a subcutaneous formulation of the drug for ease of administration as compared to its intravenous infusion version. In FY26, the company expects Briumvi’s U.S. revenue to come at between $825 million and $850 million, accounting for a major chunk of the company’s overall revenue. &nbsp;“With significant market share capture since launch, we believe TG Therapeutics is well positioned to drive long-term revenue growth and cash flow. Additionally, our development programs for consolidated IV BRIUMVI dosing and self-administered subcutaneous form of BRIUMVI are expected to drive revenue acceleration over the short and mid-term if approved,” CEO Michael S. Weiss said.“In parallel, we plan to initiate multiple exploratory studies that could expand BRIUMVI beyond MS, providing an additional lever for growth and underscoring its potential as a ‘pipeline-in-a-product,’” he added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TGTX stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed within ‘extremely high’ levels.A Stocktwits user opined that the company’s revenue estimates could exceed to touch $1 billion in FY26.<stembedurl>https://www.stocktwits.com/greko50/message/641718123</stembedurl>Yet another voiced optimism for increased profits per share.<stembedurl>https://www.stocktwits.com/neilinva/message/641717512</stembedurl><a href="https://stocktwits.com/symbol/TGTX">TGTX stock</a> is up by about 1% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/uber-doordash-caused-5800-annual-tip-loss-for-delivery-workers-in-new-york-says-report/cmUXlzyR4IN">Uber, DoorDash Caused $5,800 Annual Tip Loss For Delivery Workers With Interface Design Changes In New York, Says City Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026

The company expects total revenue for full year 2025 to be about $616 million, including $594 million from sales of its Briumvi in the U.S.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

TGTX
TG Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TGTX News

TGTXTG Therapeutics Inc